JPRN-jRCT2080222013
Unknown
Phase 3
Randomized, phase III, comparative study of every-3-weeks dosing, weekly dosing of ABI-007, and weekly dosing of the conventional paclitaxel for patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Enrollment
- 730
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed, written informed consent.
- •\- Histologically or cytologically confirmed gastric adenocarcinoma.
- •\- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\.
Exclusion Criteria
- •\- Past history of severe drug hypersensitivity
- •\- Patient has pre\-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE).
- •\- Principal Investigators'(sub investigators') judgment on ineligibility
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400 mg daily versus imatinib 800 mg daily versus imatinib plus PEG interferon-alpha 2a (Pegasys) in patients with newly-diagnosed chronic phasechronic myeloid leukaemiaChronic Myeloid LeukaemiaCancerISRCTN59346371ewcastle upon Tyne Hospitals Trust (UK)2,466
Not yet recruiting
Phase 3
To Study effectiveness of oral chemotherapy with low dose immunotherapy compared with chemotherapy in Head and Neck Cancer PatientsHealth Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynxCTRI/2024/01/061661Tata Memorial Centre
Completed
Phase 3
Prospective, randomized phase III study of two intensified treatment groups [Methotrexate/Vinblastine/Adriamycin/Cisplatin (MVAC) vs. Gemcitabine/Cisplatin] in patients with inoperable or recurrent urothelial cancerurothelial cancerCancer - BladderACTRN12610000845033Hellenic Cooperative Oncology Group206
Active, not recruiting
Not Applicable
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerPatients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-PTAmgen Inc.1,100
Active, not recruiting
Not Applicable
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal CancerPatients with Previously Treated Metastatic Colorectal CancerEUCTR2005-004676-20-LTAmgen Limited1,100